Biotech Values

[RockRat]

"There have been myriad cases where the FDA inspected an applicant’s plants and ended up not approving the drug on the current review cycle."

Yeah, I was wondering about how common that was. And how common it was when the applicant passed the inspections. I agree with your bottom line, and thus I think the odds of tEnoxaparin being approved in the near to intermediate term have improved slightly.

I think I'm done with subject for now.

Regards, RockRat